CreeBDe SezeJFoxR. RESTORE Study: Effects of a 24-week natalizumab treatment interruption on immune parameters and multiple sclerosis Magnetic Resonance Imaging disease activity. Neurology2012; 78: P06.168
2.
O’ConnorPWGoodmanAKapposL. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology2011; 76: 1858–1865.
3.
VellingaMMCastelijnsJABarkhofF. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology2008; 70: 1150–1151. Epub ahead of publication 13September2007.
4.
KillesteinJVennegoorAStrijbisEM. Natalizumab drug holiday in multiple sclerosis: Poorly tolerated. Ann Neurol2010; 68: 392–395.
5.
MillerDHKhanOASheremataWABlumhardtLDRiceG, for the international natalizumab multiple sclerosis trial group. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2003; 348:15–23.
6.
BorrielloGProsperiniLMarinelliFFubelliFPozzilliC. Observations during an elective interruption of natalizumab treatment: a post-marketing study. Mult Scler2011; 17: 372–5.
7.
WestTWCreeB. Natalizumab dosage suspension: are we helping or hurting?Ann Neurol2010; 68: 395–9.
8.
MiravalleAJensenRKinkelP. Immune reconstitution inflammatory symdrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol2011; 68: 186–91.
9.
KerbratALe PageELerayE. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. J Neurol Sci2011; 308: 98–102.
10.
HellwigKHaghikiaAGoldRPregnancy and natalizumab: Results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler2011; 17: 958–963.
